Raised charges and Covax deals on order books of Pfizer, BioNTech, Moderna and AstraZeneca
Two US companies, Pfizer and Moderna, have raised the prices of their Covid-19 vaccines after data from clinical trials showed their mRNA formula was more effective than cheaper vaccines from Britain’s AstraZeneca and the American drugs maker Johnson & Johnson.
AstraZeneca and Johnson & Johnson have pledged to provide their doses on a not-for-profit basis until the pandemic ends.
Continue reading...Pfizer reportedly asked to supply 35m more doses, with final go-ahead for this year’s programme still awaited
Ministers have started ordering vaccines for a booster campaign in autumn 2022, with Pfizer reportedly being asked to supply the UK with a further 35m doses.
The government has still not give the final go-ahead for the vaccine booster programme expected this autumn, but it is understood to have placed the order with Pfizer despite the company raising its prices.
Continue reading...The firms are already taking the lion’s share of earnings from the market, as this week’s results will show
Praised for preventing hundreds of thousands of deaths and allowing a return to more normal life, Covid vaccines will also substantially benefit some pharmaceutical companies.
In June, analysts estimated the global market for the vaccines could be worth $70bn (£50bn) this year, but the figure could be even higher as the Delta variant of coronavirus spreads and scientists debate whether people will need booster shots.
Continue reading...Advanz Pharma and former private equity owners were fined £100m by markets watchdog
A pharmaceuticals firm that inflated thyroid drug prices by up to 6,000% over a decade paid out more than £400m to shareholders and directors during the same period.
London-based Advanz Pharma – and its former private equity owners HgCapital and Cinven – were fined a combined £100m by the Competition and Markets Authority (CMA) on Thursday.
Continue reading...Research increasingly suggests that extracts from the plant are effective in treating pain, anxiety, epilepsy and more, but experts still preach caution around recreational use
In 2017, Mikael Sodergren, a liver and pancreatic cancer surgeon at Imperial College healthcare NHS trust, was finding himself becoming increasingly interested in the potential role of medical cannabis in treating pain, especially the discomfort experienced by patients after complex operations.
“I hope that I do a lot of good, but unfortunately in the short term, I inflict a lot of pain with cancer surgery,” says Sodergren. “So we’re reliant on pretty nasty painkillers, such as high-strength intravenous opioids, which we’re trying to move away from. They slow patients down and they cause complications.”
Continue reading...Twenty years ago in South Africa people were dying unable to access expensive antiretrovirals. The creation of the Global Fund was gamechanging
In 2001, at the age of 22 – when I thought my life had just begun – I was diagnosed with HIV. At that time, the diagnosis felt like a death sentence. Every day, I waited for my hour to die.
However, after two months of waiting, death didn’t come.
Continue reading...Israel says technical issues have scuppered deal to give UK Covid vaccines expiring on 30 July
More than a million Pfizer/BioNTech vaccine doses held in Israel that are due to expire at the end of July may be thrown away after attempts to broker a swap deal with the UK failed.
Israel had reportedly offered the jabs to Britain in return for a similar number of vaccines that the UK is due to receive from Pfizer in September. Health authorities are racing to vaccinate as many of its adult population as possible before Covid restrictions are lifted in England later this month.
Continue reading...Whether the pharmaceutical giant jumped or was pushed, its New York deal is a significant sign of the way the wind is blowing
Johnson & Johnson said it had already jumped. New York’s attorney general suggested the pharmaceutical giant was pushed.
Either way, the American drug maker is the first to formally agree to get out of the multibillion-dollar business of selling the powerful narcotic painkillers that drove the US opioid epidemic.
Continue reading...Amid bemusement from scientists at the deluge of often undeserved criticism, the Guardian pieces together the story behind the vaccine’s successes and failures
In January 2020, when most of the world slept soundly in ignorance of the pandemic coming its way, a group of scientists at Oxford University got to work on a vaccine to save the planet. They wanted it to be highly effective, cheap, and easy to use in even the poorest countries.
Prof Sarah Gilbert, Prof Andrew Pollard and others pulled it off. With speed crucial, they designed it and launched into trials before bringing in a business partner. The giant Anglo-Swedish pharmaceutical company AstraZeneca would manufacture it, license it around the world – and not make a profit until the pandemic was over.
Continue reading...We look at the drug firms – led by Pfizer and Moderna – that are set to profit most in an unprecedented global vaccination drive
Drugmakers led by US firms Pfizer and Moderna stand to make tens of billions of dollars from their Covid-19 vaccines this year and next, given G7 governments’ pledge to vaccinate the entire world by the end of 2022, but sales are likely to drop sharply thereafter, according to analysts.
Acclaimed for allowing a return to more normal life, Covid vaccines will also substantially benefit some pharmaceutical companies. The global market for the vaccines is worth $70bn (£50bn) this year, says Karen Andersen of Morningstar.
Continue reading...But Brussels court says AstraZeneca should have used UK plants in the past to fulfil EU deliveries
The EU has failed in a legal attempt to secure an urgent 120m vaccine doses from AstraZeneca by the end of this month, while securing a judgment that sites in Oxford and Staffordshire should have been used in the past to make good on deliveries.
The court of first instance in Brussels ordered the Anglo-Swedish company to deliver just 10m more than it has already provided by the end of September, and make “best efforts”, including potentially the use of UK facilities, to provide the further 220m jabs to which it is contractually committed.
Continue reading...G7 summit hears move would slash the cost of jabs and accelerate rollout of programmes across the developing world
Britain and Germany were under intense pressure on Saturday to drop their resistance to proposals that would slash the cost of Covid-19 vaccines, following accusations that an agreement at the G7 summit to fund a billon doses will give the world’s poorest countries “crumbs from the table”.
Aid agencies said rules that protect drug patents from being illegally copied must be waived during the pandemic to accelerate the rollout of vaccines and save lives across the developing world.
Continue reading...Country aims to vaccinate 70% of people this year but experts express doubts amid supply concerns
Thailand has started its Covid vaccination campaign amid concerns over the supply of doses, which are mainly being produced locally by a royal-owned company that has no prior experience of making vaccines.
Thailand aims to vaccinate 70% of the population before the end of the year, and is relying primarily on AstraZeneca doses produced by Siam Bioscience, a company owned by King Maha Vajiralongkorn. The company is also due to supply vaccines to eight other countries in the region.
Continue reading...Exclusive: group urges prime minister to tackle ‘desperate shortage’ in developing nations
Boris Johnson has a “moral duty” to immediately start matching each vaccine administered at home with a donated dose to poorer countries across the world, a cross-party group of MPs and peers has said.
Several Tory backbenchers joined the call, which puts further pressure on the prime minister to boost supplies given to developing nations facing a “desperate shortage” of jabs.
Continue reading...AstraZeneca and Johnson & Johnson jabs have caused rare blood clots but scientists say they can be redesigned to avoid problem
A team of German scientists believe that they have worked out why some people given the AstraZeneca and Johnson & Johnson vaccines against Covid-19 develop blood clots – and claim they can tell the manufacturers how to improve the vaccine to avoid it.
The key is in the adenovirus – the common cold virus that is used to deliver the spike protein of the coronavirus into the body, say Rolf Marschalek, a professor at Goethe university in Frankfurt, and colleagues. The mRNA vaccines developed by Pfizer/BioNTech and Moderna do not use this delivery system and there have been no blood clotting cases linked to them.
Continue reading...Commission demands €10 per dose for each day of delay as compensation
The European Commission has demanded an urgent court order requiring AstraZeneca to deliver millions more vaccines to the bloc or face a hefty fine, in a case that may reflect its anger more than its need for doses.
“AstraZeneca did not even try to respect the contract,” the EU’s lawyer, Rafaël Jafferali, told a court in Brussels on Wednesday, saying the EU wanted €10 per dose for each day of delay as compensation for the company’s alleged non-compliance.
Continue reading...Moderna becomes second manufacturer to announce successful trial results in adolescents
Mass vaccination of children against Covid-19 moved a step closer as Moderna became the second manufacturer to announce successful trial results, showing its vaccine can stop transmission in people aged 12 to 18.
Pfizer/BioNTech’s vaccine has already been given emergency approval for adolescents aged 12 to 15 in the US by the regulator, the Food and Drug Administration (FDA), after its trials were said to show better efficacy even than in participants aged 16 to 25. It has begun a trial in young children, from six months to 11 years old.
Continue reading...Pascal Soriot defends firm and says its booster jab has performed well against new Covid variants in trials
The chief executive of AstraZeneca has defended the company against “armchair generals” and said its vaccine has a future.
Pascal Soriot disclosed the UK had priority access to the jab in a deal with Oxford University in return for investment and that it was only slightly less effective against the India variant than the strain identified in Kent.
Continue reading...Efforts in Africa and elsewhere hit by decision not to export AstraZeneca jab until end of year
Vaccine programmes across Africa and much of the developing world will suffer big delays after the world’s biggest producer said it would not be exporting the Oxford/AstraZeneca vaccine until the end of the year.
“We continue to scale up manufacturing and prioritise India … We also hope to start delivering to Covax and other countries by the end of this year,” Adar Poonawalla, chief executive of the Serum Institute of India (SII), said in a statement on Tuesday.
Continue reading...Covid vaccine maker passes its remuneration policy but suffers sizeable rebellion
AstraZeneca has suffered a substantial shareholder rebellion over proposals to hand its chief executive, Pascal Soriot, bigger bonus awards for the second consecutive year.
Nearly 40% voted against the policy, which could hand him pay and perks of nearly £18m for 2021.
Continue reading...